The pediatric preclinical testing program: Description of models and early testing results-Reference-Cited by-同舟云学术

The pediatric preclinical testing program: Description of models and early testing results

Published:2006-10-25 Issue:7 Volume:49 Page:928-940
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Houghton Peter J.¹,Morton Christopher L.¹,Tucker Chandra¹,Payne Debbie¹,Favours Edward¹,Cole Claire¹,Gorlick Richard²,Kolb E. Anders²,Zhang Wendong²,Lock Richard³,Carol Hernan³,Tajbakhsh Mimi³,Reynolds C. Patrick⁴,Maris John M.⁵,Courtright Joshua⁵,Keir Stephen T.⁶,Friedman Henry S.⁶,Stopford Charles⁶,Zeidner Joseph⁶,Wu Jianrong¹,Liu Tiebin¹,Billups Catherine A.¹,Khan Javed⁷,Ansher Sherry⁸,Zhang Jian⁸,Smith Malcolm A.⁸

Affiliation:

1. St. Jude Children's Research Hospital, Memphis, Tennessee

2. The Children's Hospital at Montefiore, Bronx, New York

3. Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia

4. Children's Hospital of Los Angeles, Los Angeles, California

5. Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania

6. Duke University Medical Center, Durham, North Carolina

7. Pediatric Oncology Branch, Oncogenomics Section, National Cancer Institute (NCI), Bethesda, Maryland

8. Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland

Funder

National Cancer Institute

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.21078

Reference39 articles.

1. ReisLA PercyCL BuninGR.Cancer incidence and survival among children and adoloescents. United States SEER Program 1975–1995. NIH (Pub. No. 99–4649. Volume Introduction—SEER Pediatric Monograph. National Cancer Institute Bethesda MD;1999. pp1–15.

2. GurneyJG YoungJL RoffersSD et al.Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995 NIH (Pub. 99‐4649). National Cancer Institute SEER Program1999.111–124.

3. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.

4. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents;Friedman HS;Cancer Res,1988

Cited by 401 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma;2023-12-08

2. Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer;Nature Communications;2023-11-22

3. Hallmark discoveries in the biology of Wilms tumour;Nature Reviews Urology;2023-10-17

4. Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma;Translational Pediatrics;2023-10

5. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors;Communications Biology;2023-09-18